Archives
In Vitro Drug Response Metrics in Cancer Research
2026-08-31
Hannah R. Schwartz’s dissertation separates relative viability from fractional viability to clarify how cancer drugs produce growth arrest and cell killing. Its central implication is practical: drug-response studies should measure proliferation and death as related but distinct outcomes, ideally across time rather than at one endpoint.
Merimepodib (VX-497) Research Workflows
2026-08-30
Merimepodib (VX-497) enables controlled IMPDH inhibition for antiviral, lymphocyte, and proliferation assays. This workflow guide translates recent PEDV metabolism findings into practical experimental design, controls, and troubleshooting strategies.
ARCA EGFP mRNA: Storage-to-Assay Guide
2026-08-29
ARCA EGFP mRNA (5-moUTP) is a polyadenylated mRNA reporter for controlled fluorescence readouts in mammalian cells. This guide connects molecular design with storage, handling, assay architecture, and the practical limits of translating LNP-RNA stability findings to reporter workflows.
Cyclic di-GMP: Biofilm and STING Workflows
2026-08-28
Cyclic di-GMP connects bacterial biofilm persistence studies with mammalian STING-based immune modulation. This practical guide covers formulation, assay design, protocol starting points, controls, and troubleshooting for infection biology and cancer immunotherapy research.
Merimepodib (VX-497) IMPDH Research Workflow
2026-08-28
Merimepodib (VX-497) provides a reversible way to interrogate IMPDH-dependent guanine nucleotide biosynthesis in antiviral, lymphocyte, and cell-proliferation models. This applied guide connects formulation, dose selection, orthogonal validation, and troubleshooting to recent evidence that PEDV depends on host IMPDH activity.
Dual-Action Inhibitors and p38α Dephosphorylation
2026-08-27
The reference study shows that kinase inhibitors can do more than block p38α catalytic activity: selected compounds also expose the activation-loop phospho-threonine and accelerate its removal by WIP1. By combining biochemical dephosphorylation assays with X-ray crystallography, the work establishes kinase conformation as a potential lever for improving inhibitor specificity, durability, and pathway control.
MK-1775: Wee1 Kinase Inhibitor Workflow
2026-08-27
Use MK-1775 to interrogate Wee1-dependent checkpoint control, then separate growth arrest from true cell killing with orthogonal readouts. This workflow is especially useful for testing DNA-damage combinations in p53-deficient models without overinterpreting a single viability endpoint.
Multiple Myeloma Cell Lines: Mutations and Drug Response
2026-08-26
Vikova and colleagues used whole-exome sequencing across a genetically diverse panel of human multiple myeloma cell lines to define recurrent coding mutations, altered pathways, and links to drug response. The study provides a practical framework for selecting cell-line models and developing hypotheses about disease progression and treatment resistance.
BOP Reagent Workflow for Peptide and Prodrug Synthesis
2026-08-26
BOP reagent supports controlled carboxyl group activation for amide bond formation, phenyl ester preparation, and blocked amino acid derivative workflows. This article connects practical coupling design with the carrier-free triterpene prodrug strategy reported for oral squamous cell carcinoma, while clearly separating established chemistry from forward-looking applications.
G007-LK: From Tankyrase Biology to Translation
2026-08-25
G007-LK is a selective tankyrase 1/2 inhibitor that connects TNKS1/2 enzymatic control with AXIN stabilization, β-catenin degradation induction, and Hippo pathway modulation. This thought-leadership guide helps translational researchers design stronger mechanistic studies across APC mutation colorectal cancer research and hepatocellular carcinoma models while keeping pharmacologic and clinical limitations in view.
Tetrandrine Workflows for Ion Channel Research
2026-08-25
Build reproducible Tetrandrine assays for calcium-channel signaling, inflammation, and cancer biology research with practical stock-preparation and troubleshooting guidance. The workflow also shows how to distinguish membrane-targeted experiments from computational natural-product screening claims.
RNA Clean and Concentrator Kit: Workflow Guide
2026-08-24
The RNA Clean and Concentrator Kit is a membrane-based RNA purification spin column workflow for rapid cleanup of RNA from enzymatic reactions. The K1069 format is optimized for single-stranded RNA longer than 100 nucleotides and double-stranded RNA longer than 200 base pairs across a stated recovery range of 1 ng to 500 μg.
Saquinavir in HIV Protease and Permeability Workflows
2026-08-24
Saquinavir combines a well-defined antiviral mechanism with a useful test case for enzyme, membrane-interaction, and MS-compatible permeability workflows. This guide shows how to connect HIV protease inhibition with biomimetic IAM-LC and OT-CEC assays while separating established evidence from method-development recommendations.
Masitinib (AB1010): KIT/PDGFR Research Guide
2026-08-23
Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for selective KIT, PDGFRα, and PDGFRβ pathway studies. It is appropriate for defined cancer, mast cell, and inflammatory research workflows, but not for aqueous or ethanol-based assays, broad-spectrum kinase profiling, or clinical treatment decisions.
GSK 2837808A for LDHA Metabolism Workflows
2026-08-22
GSK 2837808A is a potent, selective LDHA inhibitor for connecting lactate production with glucose use in cancer-cell assays. This workflow shows how to control exposure, quantify metabolic effects, and interpret results alongside the NAT1–ENO1–lactate pathway described in colorectal cancer research.
613 records 10/41 page Previous Next First page 上5页 678910 下5页 Last page